Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)	Total	Cumulative Effect, Period of Adoption, Adjustment	Preferred stock	Common Stock	Additional Paid-In Capital	Additional Paid-In Capital Cumulative Effect, Period of Adoption, Adjustment	Treasury Stock	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Loss	Non-controlling Interest
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Ending balance (in shares)				92,490,768
Beginning balance (in shares) at Dec. 31, 2020			23,219,613
Beginning balance at Dec. 31, 2020	$ 622,948,000		$ 406,665,000	$ 9,000	$ 853,824,000		$ 0	$ (626,456,000)			$ (11,094,000)
Beginning balance (in shares) at Dec. 31, 2020				92,490,768
Beginning balance (in shares) at Dec. 31, 2020							(800,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of series AA preferred stock (in shares)			23,219,613	46,439,226
Conversion of Series AA Preferred Stock	0		$ (406,665,000)	$ 5,000	406,660,000
Exercise of common stock warrants (in shares)				536,825
Exercise of common stock warrants	15,803,000				15,803,000
Recognition of debt discount on 2026 Convertible Notes	88,059,000				88,059,000
Exercise of stock options (in shares)				1,082,964
Exercise of stock options	776,000				776,000
Issuance of treasury stock in connection with acquisition (in shares)							623,068
Issuance of treasury stock in connection with acquisition	8,538,000				8,538,000
Stock-based compensation	9,374,000				9,374,000
Other	(5,000)				(5,000)
Less: net loss attributable to non-controlling interest	(76,000)										(76,000)
Net loss attributable to common stockholders	(70,110,000)							(70,110,000)
Ending balance (in shares) at Mar. 31, 2021			0
Ending balance at Mar. 31, 2021	675,307,000		$ 0	$ 14,000	1,383,029,000		$ 0	(696,566,000)			(11,170,000)
Ending balance (in shares) at Mar. 31, 2021							(176,932)
Beginning balance (in shares) at Dec. 31, 2020			23,219,613
Beginning balance at Dec. 31, 2020	622,948,000		$ 406,665,000	$ 9,000	853,824,000		$ 0	(626,456,000)			(11,094,000)
Beginning balance (in shares) at Dec. 31, 2020				92,490,768
Beginning balance (in shares) at Dec. 31, 2020							(800,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Less: net loss attributable to non-controlling interest	(105,000)
Net loss attributable to common stockholders	(270,876,000)
Ending balance (in shares) at Sep. 30, 2021			0
Ending balance at Sep. 30, 2021	587,281,000		$ 0	$ 15,000	1,495,797,000		$ 0	(897,332,000)			(11,199,000)
Ending balance (in shares) at Sep. 30, 2021							(176,932)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Ending balance (in shares)				140,549,783
Beginning balance (in shares) at Mar. 31, 2021			0
Beginning balance at Mar. 31, 2021	675,307,000		$ 0	$ 14,000	1,383,029,000		$ 0	(696,566,000)			(11,170,000)
Beginning balance (in shares) at Mar. 31, 2021				140,549,783
Beginning balance (in shares) at Mar. 31, 2021							(176,932)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of common stock warrants (in shares)				71,428
Exercise of common stock warrants	500,000				500,000
Recognition of debt discount on 2026 Convertible Notes	(113,000)				(113,000)
Exercise of stock options (in shares)				508,664
Exercise of stock options	1,200,000				1,200,000
Stock-based compensation	24,431,000				24,431,000
Other (in shares)				(32,581)
Other	2,000				2,000
Less: net loss attributable to non-controlling interest	(15,000)										(15,000)
Net loss attributable to common stockholders	(94,915,000)							(94,915,000)
Ending balance (in shares) at Jun. 30, 2021			0
Ending balance at Jun. 30, 2021	606,397,000		$ 0	$ 14,000	1,409,049,000		$ 0	(791,481,000)			(11,185,000)
Ending balance (in shares) at Jun. 30, 2021							(176,932)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Ending balance (in shares)				141,097,294
Beginning balance (in shares) at Jun. 30, 2021				141,097,294
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock/At-the-market offering, net of offering costs (in shares)				2,412,968
Issuance of common stock/At-the-Market offering, net of offering costs	69,824,000			$ 1,000	69,823,000
Exercise of warrants (in shares)				744,997
Exercise of warrants	3,688,000				3,688,000
Exercise of stock options (in shares)				430,151
Exercise of stock options	570,000				570,000
Common stock issued in connection with note payable	0
Common stock issued in connection with note payable, shares				51,216
Stock-based compensation (in shares)				0
Stock-based compensation	12,667,000				12,667,000
Less: net loss attributable to non-controlling interest	(14,000)										(14,000)
Net loss attributable to common stockholders	(105,851,000)							(105,851,000)
Ending balance (in shares) at Sep. 30, 2021			0
Ending balance at Sep. 30, 2021	$ 587,281,000		$ 0	$ 15,000	1,495,797,000		$ 0	(897,332,000)			(11,199,000)
Ending balance (in shares) at Sep. 30, 2021							(176,932)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Ending balance (in shares)				144,736,626
Ending balance (in shares)	153,950,895			153,950,895
Beginning balance at Dec. 31, 2021	$ 670,881,000	$ (75,264,000)		$ 16,000	1,691,206,000	$ (87,946,000)		(1,009,293,000)	$ 12,682,000	$ 172,000	(11,220,000)
Beginning balance (in shares) at Dec. 31, 2021	153,950,895			153,950,895
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock/At-the-market offering, net of offering costs (in shares)				27,443,580
Issuance of common stock/At-the-Market offering, net of offering costs	$ 203,796,000			$ 2,000	203,794,000
Exercise of common stock warrants (in shares)				540,541
Exercise of common stock warrants	10,249,000				10,249,000
Exercise of stock options (in shares)				349,847
Exercise of stock options	443,000				443,000
Delivery of common stock underlying restricted stock units (in shares)				392,326
Stock-based compensation	19,449,000				19,449,000
Foreign currency translation adjustment	(2,215,000)									(2,215,000)
Less: net loss attributable to non-controlling interest	(93,000)										(93,000)
Net loss attributable to common stockholders	(140,724,000)							(140,724,000)
Ending balance at Mar. 31, 2022	$ 686,522,000			$ 18,000	1,837,195,000			(1,137,335,000)		(2,043,000)	(11,313,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting standards update	Accounting Standards Update 2020-06 [Member]
Beginning balance at Dec. 31, 2021	$ 670,881,000	$ (75,264,000)		$ 16,000	1,691,206,000	$ (87,946,000)		(1,009,293,000)	$ 12,682,000	172,000	(11,220,000)
Beginning balance (in shares) at Dec. 31, 2021	153,950,895			153,950,895
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)	565,022
Less: net loss attributable to non-controlling interest	$ (341,000)
Net loss attributable to common stockholders	(409,496,000)
Ending balance at Sep. 30, 2022	460,018,000			$ 19,000	1,889,274,000			(1,406,107,000)		(11,607,000)	(11,561,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Ending balance (in shares)				182,677,189
Beginning balance at Mar. 31, 2022	$ 686,522,000			$ 18,000	1,837,195,000			(1,137,335,000)		(2,043,000)	(11,313,000)
Beginning balance (in shares) at Mar. 31, 2022				182,677,189
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock/At-the-market offering, net of offering costs (in shares)	16,392,000			2,400,000
Issuance of common stock/At-the-Market offering, net of offering costs				$ 1,000	16,391,000
Exercise of stock options (in shares)				80,275
Exercise of stock options	$ 129,000				129,000
Delivery of common stock underlying restricted stock units (in shares)				135,603
Stock-based compensation	14,209,000				14,209,000
Foreign currency translation adjustment	(844,000)									(844,000)
Less: net loss attributable to non-controlling interest	(150,000)										(150,000)
Net loss attributable to common stockholders	(116,124,000)							(116,124,000)
Ending balance at Jun. 30, 2022	$ 600,134,000			$ 19,000	1,867,924,000			(1,253,459,000)		(2,887,000)	(11,463,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Ending balance (in shares)				185,293,067
Beginning balance (in shares) at Jun. 30, 2022				185,293,067
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock/At-the-market offering, net of offering costs (in shares)	8,530,000			1,815,351
Issuance of common stock/At-the-Market offering, net of offering costs					8,530,000
Exercise of stock options (in shares)				134,900
Exercise of stock options	$ 177,000				177,000
Delivery of common stock underlying restricted stock units (in shares)				100,213
Issuance of restricted stock in connection with Framework Agreement (in shares)	2,000,000
Stock-based compensation	$ 12,643,000				12,643,000
Foreign currency translation adjustment	(8,720,000)									(8,720,000)
Less: net loss attributable to non-controlling interest	(98,000)										(98,000)
Net loss attributable to common stockholders	(152,648,000)							(152,648,000)
Ending balance at Sep. 30, 2022	$ 460,018,000			$ 19,000	$ 1,889,274,000			$ (1,406,107,000)		$ (11,607,000)	$ (11,561,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Ending balance (in shares)	189,343,531
Shares, Outstanding				189,343,531